Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Novopharm Biotech antibodies poised to enter phase I

Aug. 19, 1997

NeoRx and Janssen enter agreement for Avicidin

Aug. 14, 1997

ImClone Systems earns manufacturing milestone from Merck KGaA

Aug. 4, 1997

GnRH conjugate vaccines prepared at Merck & Co.

July 30, 1997

FDA advisory committee recommends approval of rituximab

July 28, 1997

Bristol-Myers Squibb licenses cancer vaccines from Progenics

July 18, 1997

Low-dose interferon alfa nears phase III for the treatment of Sjogren's syndrome

July 17, 1997

Maxamine enters phase III for malignant melanoma

July 15, 1997

Jenner Technologies reports results from phase I/II trial of prostate cancer vaccine

July 9, 1997

MDX-210 shows promise in advanced kidney and prostate cancer

July 1, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...